- Home
- PBYI vs TNXP Comparison
PBYI vs TNXP Comparison
Compare PBYI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- TNXP
- Stock Information
- Founded
- PBYI 2010
- TNXP 2007
- Country
- PBYI United States
- TNXP United States
- Employees
- PBYI N/A
- TNXP N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- TNXP Health Care
- Exchange
- PBYI Nasdaq
- TNXP Nasdaq
- Market Cap
- PBYI 138.4M
- TNXP 116.9M
- IPO Year
- PBYI N/A
- TNXP N/A
- Fundamental
- Price
- PBYI $2.86
- TNXP $15.71
- Analyst Decision
- PBYI Strong Buy
- TNXP Strong Buy
- Analyst Count
- PBYI 1
- TNXP 2
- Target Price
- PBYI $7.00
- TNXP $585.00
- AVG Volume (30 Days)
- PBYI 334.3K
- TNXP 1.5M
- Earning Date
- PBYI 05-01-2025
- TNXP 05-12-2025
- Dividend Yield
- PBYI N/A
- TNXP N/A
- EPS Growth
- PBYI 37.78
- TNXP N/A
- EPS
- PBYI 0.62
- TNXP N/A
- Revenue
- PBYI $230,468,000.00
- TNXP $10,094,000.00
- Revenue This Year
- PBYI N/A
- TNXP $12.17
- Revenue Next Year
- PBYI N/A
- TNXP $789.15
- P/E Ratio
- PBYI $4.61
- TNXP N/A
- Revenue Growth
- PBYI N/A
- TNXP 29.94
- 52 Week Low
- PBYI $2.23
- TNXP $6.76
- 52 Week High
- PBYI $5.34
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- PBYI 42.27
- TNXP 44.80
- Support Level
- PBYI $2.83
- TNXP $15.23
- Resistance Level
- PBYI $2.99
- TNXP $22.25
- Average True Range (ATR)
- PBYI 0.17
- TNXP 2.36
- MACD
- PBYI -0.01
- TNXP -0.54
- Stochastic Oscillator
- PBYI 50.00
- TNXP 16.54
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.